Mesa Biotech announces that it has received Emergency Use Authorization (EUA) from the FDA for its Accula SARS-CoV-2 test, which gives COVID-19 diagnostic results in 30 minutes. The instrument is an affordable, easy to use testing platform designed for point-of-care (POC) infectious disease diagnosis. The COVID-19 test uses this patented technology to enable “near patient” testing, allowing testing outside of the central laboratory. The Accula test is visually read, using polymerase chain reaction (PCR) technology to detect SARS-CoV-2 (the virus responsible for COVID-19) via throat and nasal swab samples.

Mesa Biotech